Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABCD
DRKS00030948Phase 2Recruiting
- Sponsor
- German Center for Neurodegenerative Diseases
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Riluzole plus rituximab with Riluzole plus placebo (2 arms). Started Jul 2023; status: recruiting.
02
Drugs
rituximab
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on DRKS00030948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00030948.